semaglutide and kidney Ozempic cuts risk of death from disease, major study finds Semaglutide just got FDA-approved for

A new clinical trial, co-led by endocrinologist and diabetes expert John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine has shown that the oral form of semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease, and/or chronic kidney disease

Para aproveitar ao mximo esse processo, o momento da ingesto estratgico

doi: 10.1038/nm919 76 GejlMGjeddeAEgefjordLMllerAHansenSBVangKet al

GIP Receptor Agonism Enhances insulin secretion, improves fat metabolism, and works synergistically with GLP-1 signaling